Altimmune Historical Financial Ratios
ALT Stock | USD 7.11 0.10 1.39% |
Altimmune is presently reporting on over 111 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 2.92 or Days Sales Outstanding of 3.7 K will help investors to properly organize and evaluate Altimmune financial condition quickly.
Altimmune |
About Altimmune Financial Ratios Analysis
AltimmuneFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Altimmune investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Altimmune financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Altimmune history.
Altimmune Financial Ratios Chart
Add Fundamental
Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Operating Cash Flow Per Share
A measure of the cash generated from a company's normal business operations per share, indicating how much cash is generated from a company's business operations on a per-share basis.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Ev To Operating Cash Flow
A valuation metric comparing the company's enterprise value to its operating cash flow, indicating how many dollars of EV are generated for each dollar of operating cash flows.Most ratios from Altimmune's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Altimmune current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altimmune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.At this time, Altimmune's Research And Ddevelopement To Revenue is comparatively stable compared to the past year. Days Payables Outstanding is likely to gain to 2,104 in 2025, despite the fact that Free Cash Flow Yield is likely to grow to (0.14).
Altimmune fundamentals Correlations
Click cells to compare fundamentals
Altimmune Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Altimmune fundamentals Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Price To Sales Ratio | 35.33 | 85.74 | (11.4K) | 1.4K | 1.6K | 1.7K | |
Ptb Ratio | 1.28 | 1.9 | 4.17 | 3.09 | 2.78 | 2.92 | |
Days Sales Outstanding | 551.76 | 35.5 | (13.6K) | 4.2K | 3.7K | 3.7K | |
Book Value Per Share | 8.81 | 4.82 | 3.95 | 3.65 | 4.19 | 3.98 | |
Operating Cash Flow Per Share | (1.34) | (1.9) | (1.33) | (1.42) | (1.28) | (1.22) | |
Stock Based Compensation To Revenue | 0.31 | 1.25 | (119.13) | 24.98 | 28.72 | 30.16 | |
Capex To Depreciation | 1.15 | 22.33 | (0.61) | 0.0985 | 0.0887 | 0.0842 | |
Pb Ratio | 1.28 | 1.9 | 4.17 | 3.09 | 2.78 | 2.92 | |
Ev To Sales | 21.39 | 42.94 | (9.7K) | 1.1K | 1.3K | 1.3K | |
Free Cash Flow Per Share | (1.36) | (2.19) | (1.34) | (1.42) | (1.28) | (1.22) | |
Roic | (0.76) | (0.47) | (0.22) | (0.48) | (0.49) | (0.44) | |
Net Income Per Share | (1.91) | (2.33) | (1.81) | (1.66) | (1.49) | (1.57) | |
Payables Turnover | 54.73 | 0.27 | 0.0142 | 0.23 | 0.21 | 0.2 | |
Sales General And Administrative To Revenue | 1.61 | 3.49 | (251.97) | 42.58 | 48.96 | 51.41 | |
Research And Ddevelopement To Revenue | 6.08 | 16.9 | (1.0K) | 154.46 | 177.63 | 186.51 | |
Capex To Revenue | 0.0418 | 2.79 | (1.85) | 0.11 | 0.0993 | 0.0943 | |
Cash Per Share | 8.42 | 4.61 | 3.94 | 3.72 | 4.27 | 4.06 | |
Pocfratio | (8.4) | (4.83) | (12.33) | (7.9) | (9.09) | (8.63) | |
Interest Coverage | (5.8K) | (17.1K) | (11.0K) | (2.7K) | (3.2K) | (3.3K) | |
Capex To Operating Cash Flow | (0.009944) | (0.16) | (0.002013) | (6.2E-4) | (7.13E-4) | (7.49E-4) | |
Pfcf Ratio | (8.31) | (4.18) | (12.31) | (7.9) | (9.08) | (8.63) | |
Days Payables Outstanding | 6.67 | 1.3K | 25.8K | 1.6K | 1.4K | 2.1K | |
Income Quality | 0.7 | 0.81 | 0.74 | 0.86 | 0.99 | 0.95 | |
Roe | (0.45) | (0.22) | (0.48) | (0.46) | (0.41) | (0.43) | |
Ev To Operating Cash Flow | (5.08) | (2.42) | (10.58) | (6.13) | (7.05) | (6.7) | |
Pe Ratio | (5.9) | (3.93) | (9.11) | (6.77) | (7.79) | (7.4) | |
Return On Tangible Assets | (0.5) | (0.21) | (0.47) | (0.44) | (0.42) | (0.48) | |
Ev To Free Cash Flow | (5.03) | (2.09) | (10.56) | (6.12) | (7.04) | (6.69) | |
Earnings Yield | (0.17) | (0.25) | (0.11) | (0.15) | (0.13) | (0.14) | |
Intangibles To Total Assets | 0.25 | 0.24 | 0.0523 | 0.0567 | 0.06 | 0.054 | |
Net Debt To E B I T D A | 2.11 | 1.96 | 1.3 | 1.53 | 1.38 | 1.34 | |
Current Ratio | 19.16 | 11.17 | 11.31 | 17.26 | 19.85 | 20.96 | |
Tangible Book Value Per Share | 8.31 | 4.52 | 3.68 | 3.65 | 4.19 | 3.98 | |
Receivables Turnover | 0.66 | 10.28 | (0.0268) | 0.0878 | 0.1 | 0.0959 | |
Graham Number | 19.47 | 15.9 | 12.66 | 11.67 | 13.42 | 12.75 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Altimmune Stock Analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.